Endometriosis-associated bone loss: re-evaluating the potential role of systemic inflammation and hypoestrogenic therapies
Frontiers in Global Women's Health · 19.08.2026 · 7
DOI: 10.3389/fgwh.2026.1895443 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Global Women's Health, online erschienen am 19.08.2026. Verfasst von Farzaneh Motafeghi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Reproductive Endocrinology Research Center, Research Institute for Endocrine Molecular Biology, Research Institute for Endocrine Sciences, Shahid Beh…. Die Arbeit nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Endometriosis is frequently managed with hormonal suppression that can induce hypoestrogenism during a period when many patients are still accruing peak bone mass. This narrative review summarizes current clinical and mechanistic evidence on bone health in endometriosis and its treatments and discusses a preliminary conceptual framework for risk stratification and monitoring. This review discusses two hypothetical converging pathways: (1) an intrinsic pathway in which chronic systemic inflammation may shift bone remodeling toward resorption (via cytokine-mediated effects on osteoclastogenic and Wnt signaling pathways and oxidative stress), and (2) an iatrogenic pathway in which ovarian suppression, most notably with gonadotropin-releasing hormone agonists/antagonists and some progestin-based regimens, reduces estrogen exposure and can lead to measurable short-term bone mineral density loss. Available observational data generally do not show clinically meaningful bone mineral density deficits or excess fracture incidence in untreated endometriosis, but treatment-associated bone mineral density loss is well documented; long-term fracture outcomes and bone-quality measures remain insufficiently studied. We compare the skeletal safety signals across commonly used therapies, discuss the role and limitations of add-back therapy, and highlight when baseline evaluation and follow-up assessment (including consideration of trabecular bone score) may be warranted in higher-risk patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Reproductive Endocrinology Research Center, Research Institute for Endocrine Molecular Biology, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Foundation for Research & Education Excellence, Vestavia Hills, AL, United States.
- Faculty of Nursing and Health Sciences, Nord University, Bodø, Norway.
Zitieren
APA
Motafeghi, F., Saei Ghare Naz, M., Ramezani Tehrani, F., & Behboudi-Gandevani, S. (2026). Endometriosis-associated bone loss: re-evaluating the potential role of systemic inflammation and hypoestrogenic therapies. Frontiers in Global Women's Health, 7. https://doi.org/10.3389/fgwh.2026.1895443
Vancouver
Motafeghi F, Saei Ghare Naz M, Ramezani Tehrani F, Behboudi-Gandevani S. Endometriosis-associated bone loss: re-evaluating the potential role of systemic inflammation and hypoestrogenic therapies. Frontiers in Global Women's Health. 2026;7. doi:10.3389/fgwh.2026.1895443
BibTeX
@article{Motafeghi2026,
author = {Motafeghi, Farzaneh and Saei Ghare Naz, Marzieh and Ramezani Tehrani, Fahimeh and Behboudi-Gandevani, Samira},
title = {Endometriosis-associated bone loss: re-evaluating the potential role of systemic inflammation and hypoestrogenic therapies},
journal = {Frontiers in Global Women's Health},
year = {2026},
volume = {7},
doi = {10.3389/fgwh.2026.1895443}
}
EUVIMED